Gender and Cardiovascular Diseases in Aging

  • José Marín-García
  • Michael J. Goldenthal
  • Gordon W. Moe


Microsomal Triglyceride Transfer Protein Mitochondrial Oxygen Consumption Physiol Regul Integr Comp Female Heart E65K Polymorphism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583–1587PubMedCrossRefGoogle Scholar
  2. 2.
    Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002;53:709–719PubMedCrossRefGoogle Scholar
  3. 3.
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49–57PubMedCrossRefGoogle Scholar
  4. 4.
    Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Women’s health initiative investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–534Google Scholar
  5. 5.
    Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17β-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004;95:692–699PubMedCrossRefGoogle Scholar
  6. 6.
    Petre RE, Quaile MP, Rossman EJ, Ratcliffe SJ, Bailey BA, Houser SR, Margulies KB. Sex-based differences in myocardial contractile reserve. Am J Physiol Regul Integr Comp Physiol 2007;292:R810–R818PubMedGoogle Scholar
  7. 7.
    Denton K, Baylis C. Physiological and molecular mechanisms governing sexual dimorphism of kidney, cardiac, and vascular function. Am J Physiol Regul Integr Comp Physiol 2007;292:R697–R699PubMedGoogle Scholar
  8. 8.
    Paul RJ, Bowman PS, Johnson J, Martin AF. Effects of gender and estrogen on myosin COOH-terminal isoforms and contractility in rat aorta. Am J Physiol Regul Integr Comp Physiol 2007;292:R751–R757PubMedGoogle Scholar
  9. 9.
    Candore G, Balistreri CR, Listi F, Grimaldi MP, Vasto S, Colonna-Romano G, Franceschi C, Lio D, Caselli G, Caruso C. Immunogenetics, gender, and longevity. Ann NY Acad Sci 2006;1089:516–537PubMedCrossRefGoogle Scholar
  10. 10.
    Huang A, Sun D, Wu Z, Yan C, Carroll MA, Jiang H, Falck JR, Kaley G. Estrogen elicits cytochrome P450 – mediated flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt phosphorylation in genomic regulation. Circ Res 2004;94:245–252PubMedCrossRefGoogle Scholar
  11. 11.
    Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, Anversa P. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26:1068–1079PubMedCrossRefGoogle Scholar
  12. 12.
    Mallat Z, Fornes P, Costagliola R, Esposito B, Belmin J, Lecomte D, Tedgui A. Age and gender effects on cardiomyocyte apoptosis in the normal human heart. J Gerontol A Biol Sci Med Sci 2001;56:M719–M723.PubMedGoogle Scholar
  13. 13.
    Bernecker OY, Huq F, Heist EK, Podesser BK, Hajjar RJ. Apoptosis in heart failure and the senescent heart. Cardiovasc Toxicol 2003;3:183–190PubMedCrossRefGoogle Scholar
  14. 14.
    Goldspink DF, Burniston JG, Tan LB. Cardiomyocyte death and the ageing and failing heart. Exp Physiol 2003;88:447–458PubMedCrossRefGoogle Scholar
  15. 15.
    Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chem Biol Interact 2006;163:29–37PubMedCrossRefGoogle Scholar
  16. 16.
    Powell SR. The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 2006;291:H1–H19PubMedCrossRefGoogle Scholar
  17. 17.
    Boddaert J, Mallat Z, Fornes P, Esposito B, Lecomte D, Verny M, Tedgui A, Belmin J. Age and gender effects on apoptosis in the human coronary arterial wall. Mech Ageing Dev 2005;126:678–684PubMedCrossRefGoogle Scholar
  18. 18.
    Regitz-Zagrosek V, Lehmkuhl E, Lehmkuhl HB, Hetzer R. Gender aspects in heart failure. Pathophysiology and medical therapy. Arch Mal Coeur Vaiss 2004;97:899–908PubMedGoogle Scholar
  19. 19.
    Radin MJ, Holycross BJ, Sharkey LC, Shiry L, McCune SA. Gender modulates activation of renin-angiotensin and endothelin systems in hypertension and heart failure. J Appl Physiol 2002;92:935–940PubMedGoogle Scholar
  20. 20.
    Yanes LL, Romero DG, Iles JW, Iliescu R, Gomez-Sanchez C, Reckelhoff JF. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2006;291:R383–R390PubMedGoogle Scholar
  21. 21.
    Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P, Weiske J, Pregla R, Hetzer R, Regitz-Zagrosek V. Estrogen receptor alpha up-regulation and redistribution in human heart failure. FASEB J 2006;20:926–934PubMedCrossRefGoogle Scholar
  22. 22.
    Vary TC, Kimball SR, Sumner A. Sex-dependent differences in the regulation of myocardial protein synthesis following long-term ethanol consumption. Am J Physiol Regul Integr Comp Physiol 2007;292:R778–R787PubMedGoogle Scholar
  23. 23.
    Dimitrow PP, Czarnecka D, Strojny JA, Kawecka-Jaszcz K, Dubiel JS. Impact of gender on the left ventricular cavity size and contractility in patients with hypertrophic cardiomyopathy. Int J Cardiol 2001;77:43–48PubMedCrossRefGoogle Scholar
  24. 24.
    Dimitrow PP, Czarnecka D, Kawecka-Jaszcz K, Dubiel JS. The influence of age on gender-specific differences in the left ventricular cavity size and contractility in patients with hypertrophic cardiomyopathy. Int J Cardiol 2003;88:11–16PubMedCrossRefGoogle Scholar
  25. 25.
    Lin CL, Chiang CW, Shaw CK, Chu PH, Chang CJ, Ko YL. Gender differences in the presentation of adult obstructive hypertrophic cardiomyopathy with resting gradient: a study of 122 patients. Jpn Circ J 1999;63:859–864PubMedCrossRefGoogle Scholar
  26. 26.
    Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. Am J Cardiol 2003;91:1195–1198PubMedCrossRefGoogle Scholar
  27. 27.
    Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480–487PubMedCrossRefGoogle Scholar
  28. 28.
    Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 2003;42:2128–2134PubMedCrossRefGoogle Scholar
  29. 29.
    Adams KF Jr, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 1999;99:1816–1821PubMedGoogle Scholar
  30. 30.
    McKee PA, Castelli WP, McNamara PM, Kannel WB. Natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971;285:1441–1446PubMedCrossRefGoogle Scholar
  31. 31.
    Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107–115PubMedGoogle Scholar
  32. 32.
    Adams KF, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, Jensen LR, Tomasko L, Koch G. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781–1788PubMedCrossRefGoogle Scholar
  33. 33.
    Biondi-Zoccai GG, Baldi A, Biasucci LM, Abbate A. Female gender, myocardial remodeling and cardiac failure: are women protected from increased myocardiocyte apoptosis? Ital Heart J 2004;5:498–504PubMedGoogle Scholar
  34. 34.
    Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, Kajstura J, Anversa P. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856–866PubMedGoogle Scholar
  35. 35.
    Crabbe DL, Dipla K, Ambati S, Zafeiridis A, Gaughan JP, Houser SR, Margulies KB. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 2003;41:300–306PubMedCrossRefGoogle Scholar
  36. 36.
    Meldrum DR, Wang M, Tsai BM, Kher A, Pitcher JM, Brown JW, Meldrum KK. Intracellular signaling mechanisms of sex hormones in acute myocardial inflammation and injury. Front Biosci 2005;10:1835–1867PubMedCrossRefGoogle Scholar
  37. 37.
    Bae S, Zhang L. Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: focus on Akt and protein kinase C signaling. J Pharmacol Exp Ther 2005;315:1125–1135PubMedCrossRefGoogle Scholar
  38. 38.
    Kuhar P, Lunder M, Drevensek G. The role of gender and sex hormones in ischemic-reperfusion injury in isolated rat hearts. Eur J Pharmacol. 2007 Feb 1Google Scholar
  39. 39.
    Griffin M, Lee HW, Zhao L, Eghbali-Webb M. Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen. Mol Cell Biochem 2000;215:21–30PubMedCrossRefGoogle Scholar
  40. 40.
    Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS. Cause-and-effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 2002;283:H518–H525PubMedGoogle Scholar
  41. 41.
    Stewart JA Jr, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS, Dell’Italia LJ. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol 2003;35:311–319PubMedCrossRefGoogle Scholar
  42. 42.
    Chancey AL, Brower GL, Janicki JS. Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function. Am J Physiol Heart Circ Physiol 2002;282:H2152–H2158PubMedGoogle Scholar
  43. 43.
    Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol 2005;289:H316–H321PubMedCrossRefGoogle Scholar
  44. 44.
    Dash R, Frank KF, Carr AN, Moravec CS, Kranias EG. Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium. J Mol Cell Cardiol 2001;33:1345–1353PubMedCrossRefGoogle Scholar
  45. 45.
    Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW 2nd, MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 2001;276:24145–24152PubMedCrossRefGoogle Scholar
  46. 46.
    Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007;49:241–251PubMedCrossRefGoogle Scholar
  47. 47.
    Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005;112:2254–2262PubMedCrossRefGoogle Scholar
  48. 48.
    Masoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, Ordin DL, Krumholz HM. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217–223PubMedCrossRefGoogle Scholar
  49. 49.
    Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res 2002;53:740–751PubMedCrossRefGoogle Scholar
  50. 50.
    Kelley GP, Stellingworth MA, Broyles S, Glancy DL. Electrocardiographic findings in 888 patients > or =90 years of age. Am J Cardiol 2006;98:1512–1514PubMedCrossRefGoogle Scholar
  51. 51.
    Peters RW, Gold MR. The influence of gender on arrhythmias. Cardiol Rev 2004;12:97–105PubMedCrossRefGoogle Scholar
  52. 52.
    Larsen JA, Kadish AH. Effects of gender on cardiac arrhythmias. J Cardiovasc Electrophysiol 1998;9:655–664PubMedCrossRefGoogle Scholar
  53. 53.
    Schulze-Bahr E, Kirchhof P, Eckardt L, Bertrand J, Breithardt G. Gender differences in cardiac arrhythmias. Herz 2005;30:390–400PubMedCrossRefGoogle Scholar
  54. 54.
    Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin Cardiol 2002;25:49–56PubMedCrossRefGoogle Scholar
  55. 55.
    Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen city heart study). Am J Cardiol 2003;92:1419–1423PubMedCrossRefGoogle Scholar
  56. 56.
    Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Copenhagen city heart study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen city heart study). Am J Cardiol 2004;94:889–894PubMedCrossRefGoogle Scholar
  57. 57.
    Gurevitz OT, Varadachari CJ, Ammash NM, Malouf JF, Rosales AG, Herges RM, Bruce CJ, Somers VK, Hammill SC, Gersh BJ, Friedman PA. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J 2006;152:155.e9–13PubMedGoogle Scholar
  58. 58.
    Camm J. Medical management of atrial fibrillation: state of the art. J Cardiovasc Electrophysiol 2006;17 Suppl 2:S2–S6CrossRefGoogle Scholar
  59. 59.
    Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P, Frison L, Halperin JL. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006;27:1947–1953PubMedCrossRefGoogle Scholar
  60. 60.
    Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2005;112:1687–1691PubMedCrossRefGoogle Scholar
  61. 61.
    Rienstra M, Van Veldhuisen DJ, Hagens VE, Ranchor AV, Veeger NJ, Crijns HJ, Van Gelder IC. RACE investigators. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol 2005;46:1298–1306PubMedCrossRefGoogle Scholar
  62. 62.
    Gerstenfeld EP, Callans D, Dixit S, Lin D, Cooper J, Russo AM, Verdino R, Weiner M, Zado E, Marchlinski FE. Characteristics of patients undergoing atrial fibrillation ablation: trends over a seven-year period 1999–2005. J Cardiovasc Electrophysiol 2007;18:23–28PubMedCrossRefGoogle Scholar
  63. 63.
    Snyder JW, Basta LL, Woolson RF. The relative risk of spontaneous complete atrioventricular block in elderly patients with impaired intra-ventricular conduction. J Electrocardiol 1975;8:95–102PubMedCrossRefGoogle Scholar
  64. 64.
    Kawasaki R, Machado C, Reinoehl J, Fromm B, Baga JJ, Steinman RT, Lehmann MH. Increased propensity of women to develop torsades de pointes during complete heart block. J Cardiovasc Electrophysiol 1995;6:1032–1038PubMedCrossRefGoogle Scholar
  65. 65.
    Nakagawa M, Takahashi N, Nobe S, Ichinose M, Ooie T, Yufu F, Shigematsu S, Hara M, Yonemochi H, Saikawa T. Gender differences in various types of idiopathic ventricular tachycardia. J Cardiovasc Electrophysiol 2002;13:633–638PubMedCrossRefGoogle Scholar
  66. 66.
    Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A. International long QT syndrome registry. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 2003;42:103–109PubMedCrossRefGoogle Scholar
  67. 67.
    Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischaemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The stroke prevention in atrial fibrillation (SPAF) investigators. Stroke 1999;30:1223–1229PubMedGoogle Scholar
  68. 68.
    Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients >60 years of age with aortic stenosis. Am J Cardiol 1994;74:794–798PubMedCrossRefGoogle Scholar
  69. 69.
    Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGaughey D, Karp RB. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86:1099–1107PubMedGoogle Scholar
  70. 70.
    Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 2005;280:26339–26348PubMedCrossRefGoogle Scholar
  71. 71.
    Jazbutyte V, Hu K, Kruchten P, Bey E, Maier SK, Fritzemeier KH, Prelle K, Hegele-Hartung C, Hartmann RW, Neyses L, Ertl G, Pelzer T. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension 2006;48:579–586PubMedCrossRefGoogle Scholar
  72. 72.
    Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohe C, Doevendans PA. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 2006;26:1524–1530Google Scholar
  73. 73.
    Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998;98:256–261PubMedGoogle Scholar
  74. 74.
    Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B, Callies F. Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res 2003;57:370–378PubMedCrossRefGoogle Scholar
  75. 75.
    Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 2004;145:951–958PubMedCrossRefGoogle Scholar
  76. 76.
    Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 2005;280:29661–29666PubMedCrossRefGoogle Scholar
  77. 77.
    Barud W, Makaruk B, Myslinski W, Palusinski R, Hanzlik J. Hypertension, and not sex hormones or insulin resistance affects left ventricular mass in aging men. Ann Univ Mariae Curie Sklodowska [Med] 2004;59:232–236Google Scholar
  78. 78.
    Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995;92:805–810PubMedGoogle Scholar
  79. 79.
    Peter I, Shearman AM, Vasan RS, Zucker DR, Schmid CH, Demissie S, Cupples LA, Kuvin JT, Karas RH, Mendelsohn ME, Housman DE, Benjamin EJ. Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens 2005;18:1388–1395PubMedCrossRefGoogle Scholar
  80. 80.
    Leibowitz D, Dresner-Pollak R, Dvir S, Rokach A, Reznik L, Pollak A. Association of an estrogen receptor-alpha gene polymorphism with left ventricular mass. Blood Press 2006;15:45–50PubMedCrossRefGoogle Scholar
  81. 81.
    Figtree GA, Kindmark A, Lind L, Grundberg E, Speller B, Robinson BG, Channon KM, Watkins H. Novel estrogen receptor alpha promoter polymorphism increases ventricular hypertrophic response to hypertension. J Steroid Biochem Mol Biol 2007;103:110–118PubMedCrossRefGoogle Scholar
  82. 82.
    Berul CI, Christe ME, Aronovitz MJ, Maguire CT, Seidman CE, Seidman JG, Mendelsohn ME. Familial hypertrophic cardiomyopathy mice display gender differences in electrophysiological abnormalities. J Interv Card Electrophysiol 1998;2:7–14PubMedCrossRefGoogle Scholar
  83. 83.
    Olsson MC, Palmer BM, Leinwand LA, Moore RL. Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2001;280:H1136–H1144PubMedGoogle Scholar
  84. 84.
    Maass AH, Ikeda K, Oberdorf-Maass S, Maier SK, Leinwand LA. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T. Circulation 2004;110:2102–2109PubMedCrossRefGoogle Scholar
  85. 85.
    Stefanelli CB, Rosenthal A, Borisov AB, Ensing GJ, Russell MW. Novel troponin T mutation in familial dilated cardiomyopathy with gender-dependant severity. Mol Genet Metab 2004;83:188–196PubMedCrossRefGoogle Scholar
  86. 86.
    Laurent S, Boutouyrie P, Benetos A. Pathophysiology of hypertension in the elderly. Am J Geriatr Cardiol 2002;11:34–39PubMedCrossRefGoogle Scholar
  87. 87.
    Breithaupt-Grogler K, Belz GG. Epidemiology of the arterial stiffness. Pathol Biol (Paris) 1999;47:604–613Google Scholar
  88. 88.
    Ahimastos AA, Formosa M, Dart AM, Kingwell BA. Gender differences in large artery stiffness pre- and post puberty. J Clin Endocrinol Metab 2003;88:5375–5380PubMedCrossRefGoogle Scholar
  89. 89.
    Mullick AE, Walsh BA, Reiser KM, Rutledge JC. Chronic estradiol treatment attenuates stiffening, glycoxidation, and permeability in rat carotid arteries. Am J Physiol Heart Circ Physiol 2001;281:H2204–H2210PubMedGoogle Scholar
  90. 90.
    Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002;53:688–708PubMedCrossRefGoogle Scholar
  91. 91.
    Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 2005;46:249–254PubMedCrossRefGoogle Scholar
  92. 92.
    Peter I, Shearman AM, Zucker DR, Schmid CH, Demissie S, Cupples LA, Larson MG, Vasan RS, D’agostino RB, Karas RH, Mendelsohn ME, Housman DE, Levy D. Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens 2005;23:2193–2200PubMedCrossRefGoogle Scholar
  93. 93.
    Fernandez-Fernandez JM, Tomas M, Vazquez E, Orio P, Latorre R, Senti M, Marrugat J, Valverde MA. Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension. J Clin Invest 2004;113:1032–1039PubMedCrossRefGoogle Scholar
  94. 94.
    Senti M, Fernandez-Fernandez JM, Tomas M, Vazquez E, Elosua R, Marrugat J, Valverde MA. Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk. Circ Res 2005;97:1360–1365PubMedCrossRefGoogle Scholar
  95. 95.
    Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Wessel TR, Arant CB, Pohost GM, Lerman A, Quyyumi AA, Sopko G. WISE investigators. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47:S4–S20PubMedCrossRefGoogle Scholar
  96. 96.
    Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Pepine CJ, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Lerman A, Quyyumi AA, Sopko G. WISE investigators. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47:S21–S29PubMedCrossRefGoogle Scholar
  97. 97.
    Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000;342:829–835PubMedCrossRefGoogle Scholar
  98. 98.
    Pepine CJ, Kerensky RA, Lambert CR, Smith KM, von Mering GO, Sopko G, Bairey Merz CN. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol 2006;47:S30–S35PubMedCrossRefGoogle Scholar
  99. 99.
    Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BE, Hubbard LD. Retinal arteriolar narrowing and risk of coronary heart disease in men and women the Atherosclerosis risk in communities study. JAMA 2002;287:1153–1159PubMedCrossRefGoogle Scholar
  100. 100.
    Wessel TR, Arant CB, McGorray SP, Sharaf BL, Reis SE, Kerensky RA, von Mering GO, Smith KM, Pauly DF, Handberg EM, Mankad S, Olson MB, Johnson BD, Merz CN, Sopko G, Pepine CJ. NHLBI Women’s Ischemia Syndrome Evaluation (WISE). Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women’s Ischemia Syndrome Evaluation (WISE). Clin Cardiol 2007;30:69–74PubMedCrossRefGoogle Scholar
  101. 101.
    Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction 18) substudy. Circulation 2004;109:580–586PubMedCrossRefGoogle Scholar
  102. 102.
    Rosano GM, Vitale C, Lello S. Postmenopausal hormone therapy: lessons from observational and randomized studies. Endocrine 2004;24:251–254PubMedCrossRefGoogle Scholar
  103. 103.
    Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 2005;90:2708–2711PubMedCrossRefGoogle Scholar
  104. 104.
    Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217PubMedCrossRefGoogle Scholar
  105. 105.
    Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M, Genazzani AR, Mercuro G, Rosano GM. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005;50:305–311PubMedCrossRefGoogle Scholar
  106. 106.
    Murase Y, Yamada Y, Hirashiki A, Ichihara S, Kanda H, Watarai M, Takatsu F, Murohara T, Yokota M. Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women. Eur Heart J 2004;25:970–977PubMedCrossRefGoogle Scholar
  107. 107.
    Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI. Sex differences in mortality after myocardial infarction: is there evidence for an increased risk for women? Circulation 1995;91:1861–1871PubMedGoogle Scholar
  108. 108.
    Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the myocardial infarction triage and intervention registry). Am J Cardiol 1996;78:9–14PubMedCrossRefGoogle Scholar
  109. 109.
    Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. Circulation 2007;115:833–839PubMedCrossRefGoogle Scholar
  110. 110.
    Rathore SS, Wang Y, Radford MJ, Ordin DL, Krumholz HM. Sex differences in cardiac catheterization after acute myocardial infarction: the role of procedure appropriateness. Ann Intern Med. 2002;137:487–493PubMedGoogle Scholar
  111. 111.
    Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 2007;115:823–826PubMedCrossRefGoogle Scholar
  112. 112.
    Montague CR, Hunter MG, Gavrilin MA, Phillips GS, Goldschmidt-Clermont PJ, Marsh CB. Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation. Circ Res 2006;99:477–484PubMedCrossRefGoogle Scholar
  113. 113.
    Ranki HJ, Budas GR, Crawford RM, Jovanovic A. Gender-specific difference in cardiac ATP-sensitive K(+) channels. J Am Coll Cardiol 2001;38:906–915PubMedCrossRefGoogle Scholar
  114. 114.
    Wang C, Chiari PC, Weihrauch D, Krolikowski JG, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS. Gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. Anesth Analg 2006;103:274–280PubMedCrossRefGoogle Scholar
  115. 115.
    McCully JD, Toyoda Y, Wakiyama H, Rousou AJ, Parker RA, Levitsky S. Age- and gender-related differences in ischemia/reperfusion injury and cardioprotection: effects of diazoxide. Ann Thorac Surg 2006;82:117–123PubMedCrossRefGoogle Scholar
  116. 116.
    Sammut IA, Jayakumar J, Latif N, Rothery S, Severs NJ, Smolenski RT, Bates TE, Yacoub MH. Heat stress contributes to the enhancement of cardiac mitochondrial complex activity. Am J Pathol 200;158:1821–1831Google Scholar
  117. 117.
    McCully JD, Rousou AJ, Parker RA, Levitsky S. Age- and gender-related differences in mitochondrial oxygen consumption and calcium with cardioplegia and diazoxide. Ann Thorac Surg 2007;83:1102–1109PubMedCrossRefGoogle Scholar
  118. 118.
    Desrois M, Sidell RJ, Gauguier D, Davey CL, Radda GK, Clarke K. Gender differences in hypertrophy, insulin resistance and ischemic injury in the aging type 2 diabetic rat heart. J Mol Cell Cardiol 2004;37:547–555PubMedCrossRefGoogle Scholar
  119. 119.
    Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959–969PubMedCrossRefGoogle Scholar
  120. 120.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–1349PubMedCrossRefGoogle Scholar
  121. 121.
    Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. GUSTO IIA investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333–1341PubMedCrossRefGoogle Scholar
  122. 122.
    Galvani M, Ottani F, Ferrini D, Ladenson JH, Destro A, Baccos D, Rusticali F, Jaffe AS. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997;95:2053–2059PubMedGoogle Scholar
  123. 123.
    Nielsen KM, Faergeman O, Larsen ML, Foldspang A. Danish singles have a twofold risk of acute coronary syndrome: data from a cohort of 138 290 persons. J Epidemiol Community Health 2006;60:721–728PubMedCrossRefGoogle Scholar
  124. 124.
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511PubMedCrossRefGoogle Scholar
  125. 125.
    Rifai N, Warnick GR. Quality specifications and the assessment of the biochemical risk of atherosclerosis. Clin Chem Acta 2004;346:55–64CrossRefGoogle Scholar
  126. 126.
    Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:464–469PubMedCrossRefGoogle Scholar
  127. 127.
    Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 2000;21:1598–1606PubMedCrossRefGoogle Scholar
  128. 128.
    Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J. PROSPER study group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective study of pravastatin in the elderly at risk (PROSPER). Circulation 2007;115:981–989PubMedCrossRefGoogle Scholar
  129. 129.
    Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302–1306PubMedCrossRefGoogle Scholar
  130. 130.
    Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413–420PubMedGoogle Scholar
  131. 131.
    Ellsworth DL, Bielak LF, Turner ST, Sheedy PF 2nd, Boerwinkle E, Peyser PA. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J Mol Med 2001;79:390–398PubMedCrossRefGoogle Scholar
  132. 132.
    Naraoka H, Ito K, Suzuki M, Naito K, Tojo H. Analysis of gender difference of cardiac risk biomarkers using hGH-transgenic mice. Exp Anim 2006;55:1–9PubMedCrossRefGoogle Scholar
  133. 133.
    Sanz A, Hiona A, Kujoth GC, Seo AY, Hofer T, Kouwenhoven E, Kalani R, Prolla TA, Barja G, Leeuwenburgh C. Evaluation of sex differences on mitochondrial bioenergetics and apoptosis in mice. Exp Gerontol 2007;42:173–182PubMedCrossRefGoogle Scholar
  134. 134.
    Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279–284PubMedCrossRefGoogle Scholar
  135. 135.
    Nilsson PM, Engstrom G, Hedblad B, Frystyk J, Persson MM, Berglund G, Flyvbjerg A. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006;26:2758–2762PubMedCrossRefGoogle Scholar
  136. 136.
    Yan L, Ge H, Li H, Lieber SC, Natividad F, Resuello RR, Kim SJ, Akeju S, Sun A, Loo K, Peppas AP, Rossi F, Lewandowski ED, Thomas AP, Vatner SF, Vatner DE. Gender-specific proteomic alterations in glycolytic and mitochondrial pathways in aging monkey hearts. J Mol Cell Cardiol 2004;37:921–929PubMedCrossRefGoogle Scholar
  137. 137.
    Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, Corella D, Ordovas JM. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004;45:2096–2105PubMedCrossRefGoogle Scholar
  138. 138.
    Luo CH, Wang A, Zhu RH, Zhang WX, Mo W, Yu BN, Chen GL, Ou-Yang DS, Duan XH, El-Aty AM, Zhou HH. Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese. Br J Clin Pharmacol 2005;60:629–631PubMedGoogle Scholar
  139. 139.
    Arias M, Pardo J, Blanco-Arias P, Sobrido MJ, Arias S, Dapena D, Carracedo A, Goldfarb LG, Navarro C. Distinct phenotypic features and gender-specific disease manifestations in a Spanish family with desmin L370P mutation. Neuromuscul Disord 2006;16:498–503PubMedCrossRefGoogle Scholar
  140. 140.
    Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, Schork NJ, O’Connor DT. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension 2007;49:96–106PubMedCrossRefGoogle Scholar
  141. 141.
    Yamada Y, Ando F, Shimokata H. Association of gene polymorphisms with blood pressure and the prevalence of hypertension in community-dwelling Japanese individuals. Int J Mol Med 2007;19:675–683PubMedGoogle Scholar
  142. 142.
    Durst R, Jansen A, Erez G, Bravdo R, Butbul E, Ben Avi L, Shpitzen S, Lotan C, Leitersdorf E, Defesche J, Friedlander Y, Meiner V, Miserez AR. The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients. Atherosclerosis 2006;189:443–450PubMedCrossRefGoogle Scholar
  143. 143.
    Kamide K, Kokubo Y, Yang J, Matayoshi T, Inamoto N, Takiuchi S, Horio T, Miwa Y, Yoshii M, Tomoike H, Tanaka C, Banno M, Okuda T, Kawano Y, Miyata T. Association of genetic polymorphisms of ACADSB and COMT with human hypertension. J Hypertens 2007;25:103–110PubMedCrossRefGoogle Scholar
  144. 144.
    Chen W, Srinivasan SR, Li S, Boerwinkle E, Berenson GS. Gender-specific influence of NO synthase gene on blood pressure since childhood: the Bogalusa Heart Study. Hypertension 2004;44:668–673PubMedCrossRefGoogle Scholar
  145. 145.
    Stankovic A, Zivkovic M, Alavantic D. Angiotensin I-converting enzyme gene polymorphism in a Serbian population: a gender-specific association with hypertension. Scand J Clin Lab Invest 2002;62:469–475PubMedCrossRefGoogle Scholar
  146. 146.
    Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001;47:255–256PubMedGoogle Scholar
  147. 147.
    Kim Y, Kim JH, Nam YJ, Kong M, Kim YJ, Yu KH, Lee BC, Lee C. Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett 2006;407:189–194PubMedCrossRefGoogle Scholar
  148. 148.
    Kim Y, Lee C. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 2006;37:2843–2845PubMedCrossRefGoogle Scholar
  149. 149.
    Ordovas JM. Lipoprotein lipase genetic variation and gender-specific ischemic cerebrovascular disease risk. Nutr Rev 2000;58:315–318PubMedCrossRefGoogle Scholar
  150. 150.
    Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ. Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to ator-vastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 2005;178:331–338PubMedCrossRefGoogle Scholar
  151. 151.
    Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004;93:1046–1050PubMedCrossRefGoogle Scholar
  152. 152.
    Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158:183–193PubMedCrossRefGoogle Scholar
  153. 153.
    Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochloro-thiazide. Kidney Int 2002;62:1718–1723PubMedCrossRefGoogle Scholar
  154. 154.
    Garcia-Garcia AB, Gonzalez C, Real JT, Martin de Llano JJ, Gonzalez-Albert V, Civera M, Chaves FJ, Ascaso JF, Carmena R. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet Genomics 2005;15:211–218PubMedCrossRefGoogle Scholar
  155. 155.
    Hallberg P, Karlsson J, Lind L, Michaelsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Liljedahl U, Syvanen AC, Melhus H. Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment – results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA). Clin Cardiol 2004;27:287–290PubMedCrossRefGoogle Scholar
  156. 156.
    Johnson JA, Cavallari LH. Cardiovascular pharmacogenomics. Exp Physiol 2005;90:283–289PubMedCrossRefGoogle Scholar
  157. 157.
    Johnson JA. Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 2001;1:271–281PubMedCrossRefGoogle Scholar
  158. 158.
    Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, Visvikis S. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004;5:779–802PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • José Marín-García
    • 1
  • Michael J. Goldenthal
    • 2
  • Gordon W. Moe
    • 3
  1. 1.The Molecular Cardiology and Neuromuscular InstituteHighland Park
  2. 2.The Molecular Cardiology and Neuromuscular InstituteHighland Park
  3. 3.University of TorontoTorontoCanada

Personalised recommendations